Rick Gonzalez, AbbVie CEO (Pablo Martinez Monsivais/AP Images)

Ab­b­Vie toss­es its triplet ther­a­py for cys­tic fi­bro­sis, leav­ing Ver­tex to reign supreme

Ab­b­Vie went all in on cys­tic fi­bro­sis a few years ago, shelling out $245 mil­lion for a port­fo­lio of drugs from Gala­pa­gos in the hopes of de­thron­ing Ver­tex’s block­buster Trikaf­ta. On Fri­day, it be­came clear that Ver­tex still reigns supreme — at least for now.

Ab­b­Vie’s send­ing its ex­per­i­men­tal triplet ther­a­py to the scrap heap af­ter it whiffed on an in­ter­im analy­sis in a Phase II proof-of-con­cept study, ex­ecs re­vealed dur­ing the Q1 call.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.